Jiangsu Kanion Pharmaceutical Co.,Ltd.

600557

CNE000001CL7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
20.05 ^CNY	-1.33%		+2.19%	-2.29%

04-25	Jiangsu Kanion Pharmaceutical Co.,Ltd. Equity Buyback Plan Extended till February 5, 2025.	CI
04-12	Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Jiangsu Kanion Pharmaceutical Co.,Ltd. Equity Buyback Plan Extended till February 5, 2025.

April 24, 2024

On April 25, 2024, the company announced that it has extended its plan duration till February 5, 2025.

Latest news about Jiangsu Kanion Pharmaceutical Co.,Ltd.

Jiangsu Kanion Pharmaceutical Co.,Ltd. Equity Buyback Plan Extended till February 5, 2025.	04-24	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-12	CI
Tranche Update on Jiangsu Kanion Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 7, 2024.	04-01	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-10	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.	02-06	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.	02-05	CI
Kanion Pharmaceutical's Jinzhen Oral Liquid Shows Positive Result in Clinical Trial	12-08	MT
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd.(XSSC:600557) added to S&P Global BMI Index	23-09-18	CI
Kanion Pharmaceutical Gets Clinical Trial Nod in China for Pain Medicine	23-09-11	MT
Kanion Pharmaceutical Wins Chinese Drug Regulator's Nod to Trial Wubie Huangui Granules	23-09-04	MT
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-12	CI
Kanion Pharma Wins FDA Nod to Trial Myeloma Treatment Candidate in US	23-06-27	MT
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-07	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-20	CI
Kanion Pharma’s Common Cold Drug Included in China’s Medical Insurance Catalog	23-01-19	MT
Jiangsu Kanion Pharma Gets Nod for Anti-Cancer Injection Trial	23-01-11	MT
Jiangsu Kanion Pharma Gets Regulatory Nod for Traditional Chinese Medicine's Registration	22-12-30	MT
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-09	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-11	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-03	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-19	CI
Tranche Update on Jiangsu Kanion Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2021.	21-08-02	CI

Chart Jiangsu Kanion Pharmaceutical Co.,Ltd.

Duration

Period

Chart Jiangsu Kanion Pharmaceutical Co.,Ltd.

More charts

Jiangsu Kanion Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company provides capsules, oral liquid, granules, electuary, tablets, pills, patch and injections. The Company's products are applied in gynecology, orthopedics, cardiovascular and cerebrovascular, anti-infective, anti-tumor and others. The Company distributes its products mainly within domestic markets.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Jiangsu Kanion Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.05 CNY

Average target price

25.17 CNY

Spread / Average Target

+25.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGSU KANION PHARMACEUTICAL CO.,LTD.	-2.29%	1.62B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals